Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model

Maria Pufulete,1 Rachel Maishman,1 Lucy Dabner,1 Syed Mohiuddin,2 William Hollingworth,2 Chris A Rogers,1 Julian Higgins,2 Mark Dayer,3 John Macleod,2 Sarah Purdy,2 Theresa McDonagh,4 Angus Nightingale,5 Rachael Williams6 and Barnaby C Reeves1*

1Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, UK
2School of Social and Community Medicine, University of Bristol, Bristol, UK
3Department of Cardiology, Taunton and Somerset NHS Foundation Trust, Taunton, UK
4Cardiovascular Division, King’s College London, King’s College Hospital, London, UK
5Department of Cardiology, Bristol Heart Institute, Bristol Royal Infirmary, Bristol, UK
6Clinical Practice Research Datalink, Medicines and Healthcare products Regulatory Agency, London, UK

*Corresponding author barney.reeves@bristol.ac.uk

Declared competing interests of authors: Maria Pufulete is a Research Fellow who was entirely funded during the project by the British Heart Foundation and hence this fellowship paid for her time spent on this research. Rachel Maishman was a National Institute for Health Research (NIHR) Methodology Research Fellow during the course of the project and hence this fellowship paid for her time spent on this research. Lucy Dabner had a proportion of her salary paid for by the grant from the NIHR Health Technology Assessment (HTA) programme for this research (through her academic employer). Syed Mohiuddin reports receiving a grant from the NIHR HTA programme for this research (which paid for a proportion of his time through his academic employer). William Hollingworth reports receiving a grant from the NIHR HTA programme for this research (which paid for a proportion of his time through his academic employer). Chris A Rogers is a Senior Research Fellow who was entirely funded during the project by the British Heart Foundation and hence this fellowship paid for her time spent on this research. Julian Higgins reports receiving a grant from the NIHR HTA programme for this research (which paid for a proportion of his time through his academic employer). Mark Dayer reports giving a talk sponsored by Roche on point-of-care
B-type natriuretic peptide (BNP) testing. John MacLeod reports receiving a grant from the NIHR HTA programme for this research (which paid for a proportion of his time through his academic employer). Sarah Purdy reports receiving a grant from the NIHR HTA programme for this research (which paid for a proportion of her time through her academic employer). Theresa McDonagh is Clinical Audit Lead for the National Heart Failure Audit. Rachael Williams is employed by the Clinical Practice Research Datalink and reports funding from the University of Bristol to her employer, Clinical Practice Research Datalink, for access to the data during the conduct of the study; and funding from various organisations for commissioned research outside the submitted work. Barnaby C Reeves reports receiving a grant from the NIHR HTA programme for this research (which paid for a proportion of his time through his academic employer), and membership of the HTA Commissioning Board (up to 31 March 2016) and of the Systematic Reviews Programme Advisory Group (up to 5 July 2017).

Published August 2017
DOI: 10.3310/hta21400

Plain English summary

Serum BNP testing/monitoring in heart failure patients
Health Technology Assessment 2017; Vol. 21: No. 40
DOI: 10.3310/hta21400

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Heart failure (HF) affects about 500,000 people in the UK. A hormone secreted by the heart [B-type natriuretic peptide (BNP)] is raised in people with HF; higher BNP indicates more severe HF. People with HF may benefit from BNP being measured regularly, as doctors can increase medication doses to lower BNP. However, more intensive treatment may cause side effects. It is uncertain whether or not BNP monitoring works for patients and whether or not it represents value for money to the NHS.

In step 1, we combined the results of previous studies of BNP monitoring to determine which patients benefit from BNP monitoring. In step 2, to overcome the limitation that studies recruited patients who were mainly younger and healthier, we analysed data that were collected routinely in the NHS that described people diagnosed as having HF between 1 April 2005 and 31 March 2013 and their health outcomes. In step 3, we combined findings from steps 1 and 2 to find out how the cost-effectiveness of BNP monitoring varies according to patients’ characteristics.

We found that BNP monitoring is cost-effective in patients who are < 75 years old and have poor heart function. However, the effectiveness was not related to the reduction in BNP achieved or more intensive medication. BNP monitoring is not effective in older patients or those with good heart function. BNP monitoring was carried out in non-UK hospitals using a variety of methods, for example at different time intervals and with different target levels. In the UK, general practitioners care for NHS patients with HF unless they need hospital treatment. Therefore, it is not clear how BNP monitoring should be implemented and whether or not it would work in the NHS.
Health Technology Assessment

ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 4.236

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org). 

Editorial contact: journals.library@nihr.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 11/102/03. The contractual start date was in August 2013. The draft report began editorial review in June 2016 and was accepted for publication in January 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2017. This work was produced by Pufulete et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Health Technology Assessment Editor-in-Chief

Professor Hywel Williams  Director, HTA Programme, UK and Foundation Professor and Co-Director of the Centre of Evidence-Based Dermatology, University of Nottingham, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Health and Wellbeing Research Group, University of Winchester, UK

Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood  Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact:  journals.library@nihr.ac.uk